Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APLS NYSE:OGN NYSE:PRME NASDAQ:XENE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLSApellis Pharmaceuticals$19.59-2.5%$18.50$16.10▼$41.94$2.52B0.672.04 million shs2.93 million shsOGNOrganon & Co.$10.18+1.0%$9.66$8.01▼$23.10$2.65B0.63.55 million shs2.18 million shsPRMEPrime Medicine$4.21-3.2%$2.55$1.11▼$5.95$566.23M2.332.32 million shs2.16 million shsXENEXenon Pharmaceuticals$30.30-2.3%$31.50$26.74▼$46.00$2.38B1.11.43 million shs969,939 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLSApellis Pharmaceuticals-2.49%+0.62%+6.53%+12.01%-47.61%OGNOrganon & Co.+1.08%+7.56%+1.75%-16.67%-52.96%PRMEPrime Medicine-3.22%+1.94%+73.97%+149.11%-23.32%XENEXenon Pharmaceuticals-2.29%-4.08%-4.60%-19.46%-30.71%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPLSApellis Pharmaceuticals4.1918 of 5 stars4.30.00.04.41.72.50.6OGNOrganon & Co.4.7766 of 5 stars3.33.01.73.72.53.31.9PRMEPrime Medicine3.8575 of 5 stars4.41.00.00.03.25.00.6XENEXenon Pharmaceuticals3.7538 of 5 stars4.54.00.00.03.12.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPLSApellis Pharmaceuticals 2.62Moderate Buy$40.00104.19% UpsideOGNOrganon & Co. 2.50Moderate Buy$18.0076.90% UpsidePRMEPrime Medicine 2.75Moderate Buy$9.25119.71% UpsideXENEXenon Pharmaceuticals 3.00Buy$54.8280.92% UpsideCurrent Analyst Ratings BreakdownLatest PRME, OGN, APLS, and XENE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/18/2025APLSApellis PharmaceuticalsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$47.00 ➝ $50.007/16/2025APLSApellis PharmaceuticalsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$23.00 ➝ $24.007/16/2025PRMEPrime MedicineWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$8.007/2/2025APLSApellis PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$25.00 ➝ $26.006/2/2025APLSApellis PharmaceuticalsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$26.00 ➝ $29.005/27/2025PRMEPrime MedicineCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$10.00 ➝ $1.505/22/2025APLSApellis PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$49.00 ➝ $41.005/22/2025OGNOrganon & Co.BNP ParibasSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/20/2025PRMEPrime MedicineJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$10.00 ➝ $6.005/20/2025PRMEPrime MedicineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral5/20/2025PRMEPrime MedicineJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral(Data available from 7/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPLSApellis Pharmaceuticals$781.37M3.15N/AN/A$1.84 per share10.65OGNOrganon & Co.$6.29B0.42$4.99 per share2.04$1.83 per share5.56PRMEPrime Medicine$3.85M147.23N/AN/A$1.37 per share3.07XENEXenon Pharmaceuticals$9.43M246.54N/AN/A$9.90 per share3.06Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPLSApellis Pharmaceuticals-$197.88M-$1.79N/AN/AN/A-28.83%-99.19%-25.35%7/31/2025 (Estimated)OGNOrganon & Co.$864M$2.883.532.721.0511.92%227.43%7.34%8/5/2025 (Estimated)PRMEPrime Medicine-$198.13M-$1.61N/AN/AN/AN/A-107.87%-74.97%N/AXENEXenon Pharmaceuticals-$234.33M-$3.23N/AN/AN/AN/A-32.44%-30.84%8/14/2025 (Estimated)Latest PRME, OGN, APLS, and XENE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025XENEXenon Pharmaceuticals-$1.03N/AN/AN/AN/AN/A8/5/2025Q2 2025OGNOrganon & Co.$0.93N/AN/AN/A$1.55 billionN/A7/31/2025Q2 2025APLSApellis Pharmaceuticals-$0.44N/AN/AN/A$187.91 millionN/A5/12/2025Q1 2025XENEXenon Pharmaceuticals-$0.90-$0.83+$0.07-$0.83$1.64 million$7.50 million5/7/2025Q1 2025APLSApellis Pharmaceuticals-$0.36-$0.74-$0.38-$0.74$197.61 million$149.90 million5/1/2025Q1 2025OGNOrganon & Co.$0.89$1.02+$0.13$0.33$1.53 billion$1.51 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPLSApellis PharmaceuticalsN/AN/AN/AN/AN/AOGNOrganon & Co.$0.080.79%N/A2.78%N/APRMEPrime Medicine$1.4534.35%N/AN/A N/AXENEXenon PharmaceuticalsN/AN/AN/AN/AN/ALatest PRME, OGN, APLS, and XENE DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/2/2025OGNOrganon & Co.quarterly$0.020.8%5/12/20255/12/20256/12/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPLSApellis Pharmaceuticals2.764.083.62OGNOrganon & Co.16.491.671.15PRMEPrime MedicineN/A6.506.50XENEXenon PharmaceuticalsN/A17.6617.66Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPLSApellis Pharmaceuticals96.29%OGNOrganon & Co.77.43%PRMEPrime Medicine70.37%XENEXenon Pharmaceuticals95.45%Insider OwnershipCompanyInsider OwnershipAPLSApellis Pharmaceuticals6.50%OGNOrganon & Co.1.96%PRMEPrime Medicine22.93%XENEXenon Pharmaceuticals5.52%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPLSApellis Pharmaceuticals770125.68 million117.51 millionOptionableOGNOrganon & Co.4,000259.96 million254.86 millionNot OptionablePRMEPrime Medicine234134.50 million100.38 millionOptionableXENEXenon Pharmaceuticals21076.73 million72.50 millionOptionablePRME, OGN, APLS, and XENE HeadlinesRecent News About These CompaniesLegato Capital Management LLC Takes $323,000 Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)July 26 at 4:07 AM | marketbeat.comInvestors Buy Large Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE)July 24 at 3:55 AM | marketbeat.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Bought by Bank of New York Mellon CorpJuly 23 at 3:37 AM | marketbeat.comNew York State Common Retirement Fund Buys 9,851 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)July 22, 2025 | marketbeat.comMutual of America Capital Management LLC Buys New Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)July 21, 2025 | marketbeat.comJennison Associates LLC Sells 24,860 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)July 20, 2025 | marketbeat.comCenterBook Partners LP Makes New $745,000 Investment in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)July 18, 2025 | marketbeat.comTimesSquare Capital Management LLC Has $25.01 Million Stock Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)July 14, 2025 | marketbeat.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Average Recommendation of "Buy" by BrokeragesJuly 10, 2025 | marketbeat.comTraders Buy Large Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE)July 10, 2025 | marketbeat.comXenon Pharmaceuticals (NASDAQ:XENE) Shares Cross Below 200 Day Moving Average - Here's WhyJuly 5, 2025 | marketbeat.comXenon Appoints CEO Ian Mortimer as Interim CFOJuly 3, 2025 | tipranks.comXenon Pharmaceuticals Inc. Added to Russell 3000® and Russell 2000® Indexes in Annual Reconstitution - NasdaqJune 29, 2025 | nasdaq.comXenon Pharmaceuticals Joins Russell 3000® and 2000® IndexesJune 27, 2025 | tipranks.comXenon Pharmaceuticals Inc. Added to Russell 3000® and Russell 2000® Indexes in Annual ReconstitutionJune 27, 2025 | quiverquant.comQXenon Joins the Russell 3000® and Russell 2000® IndexesJune 27, 2025 | financialpost.comFXenon Joins the Russell 3000® and Russell 2000® IndexesJune 27, 2025 | globenewswire.comXenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 26, 2025 | financialpost.comFXenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 26, 2025 | globenewswire.comXenon Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:XENE)June 26, 2025 | marketbeat.comXenon Announces Appointment of Darren Cline as Chief Commercial OfficerJune 24, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePRME, OGN, APLS, and XENE Company DescriptionsApellis Pharmaceuticals NASDAQ:APLS$19.59 -0.50 (-2.49%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$19.69 +0.10 (+0.51%) As of 07/25/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.Organon & Co. NYSE:OGN$10.18 +0.11 (+1.04%) Closing price 07/25/2025 03:59 PM EasternExtended Trading$10.18 +0.01 (+0.10%) As of 07/25/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.Prime Medicine NYSE:PRME$4.21 -0.14 (-3.22%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$4.18 -0.03 (-0.59%) As of 07/25/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts.Xenon Pharmaceuticals NASDAQ:XENE$30.30 -0.71 (-2.29%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$30.75 +0.45 (+1.49%) As of 07/25/2025 05:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Intel's Turnaround Gains Credibility With Strong Q2 Report Qualcomm's Next Gear: A Growth Story Wall Street Might Be Missing Krispy Kreme: A Meme Stock Sugar Rush or a Sustainable Treat? From Zero to Hero? Why GoPro's Rally Could Be More Than It Seems CrowdStrike Scores Big With Gartner, But Valuation Is Stretched ServiceNow: The 2nd Wave of AI Spending Is Here Tractor Supply Revs Up on Forecast Hike and Bullish Signals A Smokin’ Hot Entry Point for Chipotle Stock Opens in Q3 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
